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Abstract
Aims/hypothesis Nicotinamide-N-methyltransferase (NNMT)
was recently shown to be upregulated in mouse models of
insulin resistance and obesity. So far, it is unknown whether
NNMT is regulated in human disease. We have explored the
hypothesis that white adipose tissue (WAT) NNMT expression
and plasma 1-methylnicotinamide (MNA) concentration are
increased in human insulin resistance and type 2 diabetes.
Methods NNMT expression and plasma MNAwere analysed
in three groups of individuals: (1) 199 patients undergoing
abdominal surgery; (2) 60 individuals on a 12-week exercise
programme and (3) 55 patients on a two-step bariatric surgery
programme.
Results Patients with manifest type 2 diabetes have a signifi-
cantly (approximately twofold) higher NNMT expression both
in omental and subcutaneous WAT compared with controls.
Notably, plasma MNA correlated significantly with WAT
NNMT expression in patients with type 2 diabetes (women,
r=0.59, p<0.001; men, r=0.61, p<0.001) but not in healthy
control individuals. In insulin-resistant individuals, there was
an inverse correlation between insulin sensitivity and plasma
MNA (r=0.44, p=0.01) or adipose tissue NNMT mRNA (r=
0.64, p<0.001). The latter association was confirmed in a
second cohort (n=60, r=0.78, p<0.001). Interventions im-
proving insulin sensitivity—exercise and bariatric surgery—
were associated with a significant (p<0.001) reduction in
WAT NNMT expression. Bariatric surgery was also associated
with a significant decrease in plasma MNA.
Conclusions/interpretation We demonstrate that WAT
NNMT expression is regulated in human insulin resis-
tance and type 2 diabetes and that plasma MNA corre-
lates with increased tissue NNMT expression and the
degree of insulin resistance, making it a potential bio-
marker for loss of insulin sensitivity.
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Increased abdominal adiposity, especially expansion of viscer-
al adipose tissue, has been identified as a major risk factor for
the development of insulin resistance, type 2 diabetes and
cardiovascular disease [1–3]. How visceral adiposity
contributes to the development of type 2 diabetes is
not fully understood. Mechanisms that have been pro-
posed include macrophage deposition and activation,
and release of proinflammatory cytokines and NEFA
that exacerbate systemic insulin resistance and loss of
beta cell function (reviewed in [3, 4]).
Nicotinamide, the amide form of niacin or vitamin B3, is a
precursor in the synthesis of NAD+ and NADP+, which play a
role in numerous biological processes like energy production,
regulation of cellular redox state and circadian rhythm and
longevity. Prolonged high intake of niacin or nicotinamide
has been reported to reduce insulin sensitivity in individuals
with normal or impaired glucose tolerance [5–7]. For exam-
ple, individuals at risk of type 1 diabetes who were treated
with nicotinamide at a dose of 2 g per day for 2 weeks showed
a significant decrease in systemic insulin sensitivity, which
was reversible after treatment stopped [7]. Recently, it was
observed in the HPS2-THRIVE study (Heart Protection
Study 2–Treatment of HDL to Reduce the Incidence of
Vascular Events) that, in patients with cardiovascular disease,
chronic treatment with a combination of extended-release ni-
acin and laropiprant led to a significant increase in new-onset
diabetes and disturbed glucose control in patients with
established type 2 diabetes at baseline [8]. However, the
mechanisms linking nicotinamide metabolism to insulin resis-
tance are unknown. Here we explore the hypothesis that ele-
vated nicotinamide-N-methyltransferase (NNMT) expression
and activity may play a role in the development of human
insulin resistance.
NNMT is the major nicotinamide-metabolising enzyme
and catalyses the transfer of a methyl group from S-
adenosylmethionine (SAM) to the ring nitrogen of nicotin-
amide thus yielding 1-methylnicotinamide (MNA) and S-
adenosylhomocysteine (SAH). NNMT is primarily expressed
in the liver but is also expressed in other organs including
lung, muscle, kidney, heart, skin and adipose tissue. In adipose
tissue, an increase in NNMTcatalytic activity was observed in
mice fed a high-fat diet for 3 months [9] whereas no parallel
change in liver NNMT activity was detected [9]. NNMT ex-
pression both in white adipose tissue (WAT) and in liver was
recently found to be upregulated in mouse models of obesity
and diabetes [10]. Of note, reduction in liver and WAT NNMT
expression by treatment with an antisense oligonucleotide was
shown to protect against the development of diet-induced obe-
sity and insulin resistance. Moreover, adipose tissue NNMT
expression was found to be higher in obesity-prone vs obesity-
resistant mouse strains [10].
Importantly, higher urinary concentrations of the NNMT
product MNA and its oxidation product N-methyl-2-
pyridone-5-carboxamide were observed in mouse and rat
models of type 2 diabetes and in humans with type 2 diabetes
[11]. However, it is still unclear whether plasma MNA con-
centrations are associated with adipose tissue NNMT expres-
sion, impaired insulin sensitivity or type 2 diabetes in humans.
In this context we wondered whether MNA may represent a
circulating biomarker of insulin resistance. We therefore in-
vestigated circulating MNA and adipose tissue NNMT expres-
sion in individuals with either normal glucose metabolism or
insulin resistance and type 2 diabetes in three independent
cohorts: (1) a cross-sectional cohort of 199 individuals under-
going abdominal surgery; (2) an exercise-intervention cohort
of 60 individuals on a 3-month exercise programme and (3) a
bariatric surgery intervention cohort including 55 individuals
on a two-step bariatric surgery programme. In the two inter-
vention cohorts, we assessed whether improved glucose ho-
meostasis and/or reduced body weight are associated with




We included three different cohorts with a total number of 314
individuals in our study of MNA serum concentration and
NNMT adipose tissue mRNA expression.
Individuals in all cohorts fulfilled the following inclusion
criteria: (1) absence of any acute or chronic inflammatory
disease as determined by a leucocyte count >8,000×109/l,
C-reactive protein (CrP) >952 nmol/l or clinical signs of in-
fection; (2) undetectable antibodies against GAD; (3) systolic
blood pressure <140 mmHg and diastolic blood pressure
<90 mmHg; (4) no clinical evidence of either cardiovascular
or peripheral artery disease; (5) no thyroid dysfunction; (6) no
alcohol or drug abuse; (7) no pregnancy.
All study protocols have been approved by the ethics com-
mittee of the University of Leipzig (Reg. no. 031-2006 and
017-12-23012012). All participants gave written informed
consent before taking part in the study.
Cross-sectional cohort In the cross-sectional cohort (n=199;
128 women, 71 men), we investigated MNA plasma concen-
trations and NNMT mRNA expression in paired samples of
subcutaneous and omental adipose tissue in relation to mea-
sures of obesity and glucose metabolism. Individuals involved
in these analyses underwent abdominal surgery for weight
reduction, cholecystectomy or explorative laparoscopy be-
tween 2009 and 2012. Indications for an exploratory laparos-
copy included accidents with a blunt abdominal trauma,
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diagnosis of endometriosis and treatment of intra-abdominal
adhesions. Only adipose tissue samples were included from
patients in whom laparoscopy did not identify abdominal in-
juries, inflammation or endometriosis. All participants had a
stable weight, defined as the absence of fluctuations of >10%
of body weight for at least 3 months before surgery. Adipose
tissue was immediately frozen in liquid nitrogen after explan-
tation. Histological analyses and measurement of macrophage
count in adipose tissue was performed as previously described
[12].
Exercise-intervention cohort In a second, interventional
study, we investigated adipose tissue NNMT expression in
response to a 12-week intensive exercise intervention in 60
individuals with different degrees of glucose tolerance as pre-
viously described [13]. Individuals were divided into groups
of normal glucose tolerance (NGT, n=20; 9 men, 11 women),
impaired glucose tolerance (IGT, n=20; 9 men, 11 women)
and type 2 diabetes (n=20; 11men, 9 women) on the basis of a
75 g OGTT according to the ADA criteria as previously de-
scribed [14]. For details, see electronic supplementary mate-
rial (ESM) Methods.
Bariatric surgery cohort In addition, we measured adipose
tissue NNMT mRNA expression and circulating MNA levels
at two bariatric surgery interventions. From 55 white obese
patients (38 women, 17 men), plasma samples, omental and
subcutaneous adipose tissue biopsies were obtained in the
context of a two-step bariatric surgery strategy with gastric
sleeve resection as the first step and a Roux-en-Y gastric by-
pass as second step 12±2 months later. The characteristics of
the study population have been described previously [14].
Measurement of body fat content, glucose metabolism, insulin
sensitivity
BMI was calculated as weight divided by squared height. Hip
circumference was measured over the buttocks; waist circum-
ference was measured at the midpoint between the lower ribs
and iliac crest. Percentage of body fat was measured by dual
x-ray absorptiometry. Abdominal visceral and subcutaneous
fat areas were calculated using MRI or computed tomography
scans at the level of L4–L5 in the cross-sectional study of
adipose tissue donors. Three days before the OGTT, patients
documented a high-carbohydrate diet in diet protocols. The
OGTT was performed after an overnight fast with 75 g
standardised glucose solution (Glucodex Solution 75 g;
Merieux,Montreal, QC, Canada). Venous blood samples were
taken at 0, 60 and 120min for measurement of plasma glucose
concentration. Insulin sensitivity was assessed in a subgroup
of 85 adipose-tissue donors including 52 individuals without
type 2 diabetes and 33 patients with type 2 diabetes (Table 1)
and in all participants of the intervention studies using the
HOMA-IR index or the euglycaemic–hyperinsulinaemic
clamp method as described [15]. Individuals with a glucose
infusion rate (GIR) lower than 50 μmol kg−1 min−1 were clas-
sified as insulin resistant [15].
Analyses of blood samples
All baseline blood samples were collected between
08:00 hours and 10:00 hours after an overnight fast. Plasma
insulin was measured with an enzyme immunometric assay
for the IMMULITE automated analyser (Diagnostic Products
Corporation, Los Angeles, CA, USA). Serum lipid profiles
were measured as previously described [16].
NNMT mRNA expression studies
Human NNMTmRNA expression was measured by quantita-
tive real-time RT-PCR in a fluorescent temperature cycler
using the TaqMan assay and fluorescence was detected on
an ABI PRISM 7000 sequence detector (Applied
Biosystems, Darmstadt, Germany). For details, see ESM
Methods.
Table 1 Anthropometric and clinical characteristics of individuals who
underwent abdominal surgery (cross-sectional cohort)





Age, years 56±18 53±13 0.13
Female sex, n (%) 73 (66) 55 (63) 0.63
Body weight, kg 95±41 144±41 <0.001
BMI, kg/m2 33±13 49±13 <0.001
FPGb, mmol/l 5.5±0.9 7.3±2.5 <0.001
FPIc, pmol/l 79±108 247±198 0.001
HbA1c





GIRe, μmol kg−1 min−1 87±28 35±24 <0.001
TGf, mmol/l 1.2±0.5 2.0±1.0 <0.001
LDL-Cg, mmol/l 3.1±1.0 2.7±0.8 0.04
HDL-Cg, mmol/l 1.4±0.5 1.2±0.4 0.01
Data are given as mean ± SD for parametric variables or number (column
percentage) for categorical variables
a The p values were determined using Student’s t test for continuous
parametric values and χ2 tests for categorical values
b Fasting plasma glucose, n=175 (95 no T2D, 80 T2D)
c Fasting plasma insulin, n=120 (58 no T2D, 62 T2D)
dHbA1c, n=110 (53 no T2D, 57 T2D)
e Glucose infusion rate, n=85 (52 no T2D, 33 T2D)
f Triacylglycerols, n=119 (52 no T2D, 67 T2D)
g LDL-cholesterol, HDL-cholesterol, n=116 (51 no T2D, 65 T2D)
T2D, type 2 diabetes
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Quantification of MNA concentrations in plasma
Plasma MNA was measured by liquid chromatography with
tandem mass spectrometry (LCMSMS) using an electrospray
ionisation–triple quadrupole mass spectrometer coupled to a
liquid chromatography system. See ESM Methods for further
details.
Statistical analysis
The homoscedastic two-sided Student’s t test was used to
compare clinical characteristics between different groups of
individuals (e.g. NNMT expression between non-diabetic and
diabetic individuals). The paired t test was used to compare
clinical variables within individual participants (e.g. adipose
tissueNNMT expression before and after exercise intervention
or before and after bariatric surgery). A p value <0.05 was
considered to be statistically significant.
Spearman’s correlation coefficients were calculated to
evaluate the relationships between different clinical character-
istics among the same group of individuals (e.g. to investigate
the association between plasma MNA concentrations and ad-
ipose tissueNNMTexpression). For the latter, data were log10-
transformed to achieve normal distribution.
Linear regression modelling was performed using SAS
ProcGLM (SAS version 9.2, SAS Institute, Cary, NC, USA).
Results
Cross-sectional cohort
Anthropometric, demographic and clinical characteristics of
the study participants are summarised in Table 1. Overall,
adipose tissue and plasma samples were collected from 199
individuals undergoing abdominal surgery, 88 of them having
been diagnosed with type 2 diabetes before surgery. Of the 88
patients with type 2 diabetes, 56 were treated by diet and
exercise without any pharmacotherapy, 17 received metfor-
min, 20 were treated with insulin (with or without metformin),
one received glimepiride and one pioglitazone.
Figure 1a shows the difference in adipose tissue NNMT
expression between individuals with type 2 diabetes and those
without type 2 diabetes. In both subcutaneous and omental
WAT, NNMT expression was significantly (approximately
twofold) higher in the diabetic patients than in the non-
diabetic patients, irrespective of sex. Under the assumption
of a log-normal distribution of NNMT expression, the ratio
of the geometric means of NNMT expression between patients
with type 2 diabetes and non-diabetic patients was 1.82 (95%
CI 1.22, 2.72) for omental adipose tissue in women, 1.54
(0.91, 2.44) for omental adipose tissue in men, 1.67 (1.16,
2.41) for subcutaneous adipose tissue in women and 1.52
(0.95, 2.44) for subcutaneous adipose tissue in men.
In contrast, no significant association between BMI and
adipose tissue NNMT expression was observed. There was
no correlation between NNMT expression in omental
(Fig. 1b) or subcutaneous WAT (not shown) and BMI. There
was a trend across BMI tertiles towards an increase in omental
WAT NNMT expression that was, however, not statistically
significant (p=0.2)
Interestingly, plasmaMNA concentrations did not correlate
with either omental (Fig. 2a, b) or subcutaneous (Fig. 2e, f)
adipose tissue NNMT expression in non-diabetic individuals.
However, there was a statistically significant positive associ-
ation (r=0.6, p<0.001) between plasma MNA concentration
and adipose tissue NNMT expression in both adipose depots
and for both women and men with type 2 diabetes (Fig. 2c, d
and g, h). In a linear regression analysis with NNMT expres-
sion as independent and MNA as dependent variable (both
log10-transformed), there was a significant interaction of the
Fig. 1 Differences in WAT NNMT expression with type 2 diabetes and
BMI. (a) Expression of NNMT in either omental (light-grey bars) or
subcutaneous (dark-grey bars) adipose tissue was significantly higher in
individuals with type 2 diabetes compared with non-diabetic individuals.
(b) There was no correlation between omental WAT NNMT expression
and BMI (r2=0.001). AU, arbitrary units; T2D, type 2 diabetes.
**p<0.01, *p<0.05 for indicated comparisons
802 Diabetologia (2015) 58:799–808
regression parameter with diabetes status (p=0.015 for omen-
tal, p<0.001 for subcutaneousWAT) that remained significant
after adjustment for age, BMI and sex (p=0.016 for omental,
p<0.001 for subcutaneous WAT).
Of note, although there was no significant association of
adipose tissue NNMT expression with BMI (Fig. 1b), MNA
concentrations significantly correlated with omental or subcu-
taneous adipose tissue NNMT expression in all individuals
Fig. 2 Correlation between
plasma MNA concentration and
NNMT expression in omental
(a–d) and subcutaneous (e–h)
WAT. Circles, women; triangles,
men; black symbols, non-diabetic
individuals; white symbols,
individuals with type 2 diabetes.
Data were log10-transformed to
achieve normal distribution
Correlation coefficients were as
follows: (a) r2=0.04, NS; (b)
r2=0.09, NS; (c) r2=0.35,
p<0.001; (d) r2=0.37, p<0.001;
(e) r2=0.01, NS; (f) r2=0.01, NS;
(g) r2=0.39, p<0.001; (h)
r2=0.35, p<0.001. AU, arbitrary
units; scWAT, subcutaneous WAT
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with a BMI above the median BMI of 39 kg/m2 (r=0.56 for
omental and r=0.5 for subcutaneous adipose tissue NNMT,
p<0.001 each). In contrast, in individuals with a BMI below
median we only found a significant correlation between cir-
culating MNA and omental NMMT expression (r=0.24,
p=0.02), but no significant correlation for subcutaneous
(r=0.15, p=0.15) adipose tissue (ESM Fig. 1).
In individuals for whom hyperinsulinaemic–euglycaemic
clamp data were available (n=85), NNMT expression in
omental adipose tissue was about 3.5-fold higher in insulin-
resistant individuals (n=32, p<0.001) than in insulin-sensitive
individuals (n=53) (Fig. 3a). Insulin resistancewas defined by
a GIR lower than 50 μmol kg−1 min−1 [15]. In contrast, the
difference in subcutaneous adipose tissue NNMT mRNA be-
tween insulin-resistant and insulin-sensitive individuals did
not reach statistical significance (p=0.3). In insulin-resistant
individuals, we found significant correlations between GIR
and NNMT expression in omental (Fig. 3b, r=0.64,
p<0.001) and subcutaneous adipose tissue (r=0.4, p=0.02,
ESM Fig. 2). As there was also a positive association between
plasmaMNA concentration and adipose tissue NNMT expres-
sion in this study group (Fig. 3c, r=0.66, p<0.001), plasma
MNA levels significantly correlate with the degree of insulin
resistance (Fig. 3d, r=0.44, p=0.01). These correlations were
not observed in insulin-sensitive individuals.
Exercise-intervention cohort
The association between adipose tissue NNMT expression and
insulin resistance observed in the cross-sectional cohort could
be confirmed in an independent cohort (n=60, 20 each of
individuals with NGT, IGTand type 2 diabetes) of individuals
that participated in a 12-week exercise-intervention pro-
gramme consisting of three 1 h sessions of exercise per week.
Clinical and anthropometric characteristics of study partici-
pants before and after exercise are summarised in Table 2. In
all three groups—NGT, IGT and type 2 diabetes—the physi-
cal training programme led to a significant reduction in body
weight and an improvement in glucose metabolism.
Subcutaneous adipose tissue NNMT expression was signifi-
cantly higher in patients with type 2 diabetes (2.9-fold,
p<0.001) or IGT (2.7-fold, p<0.001) than in individuals with
NGT (Fig. 4a). Importantly, endurance training led to a sig-
nificant decrease in adipose tissue NNMT expression in indi-
viduals with IGT (−21%, p<0.001) and in those with type 2
diabetes (−16%, p<0.001) but not in NGT individuals (+3%,
Fig. 3 Association of adipose tissue NNMT expression and insulin resis-
tance for the subgroup of patients for whom there were clamp data avail-
able (n=85). (a) Expression ofNNMT in omental (light-grey bars) but not
subcutaneous (dark-grey bars) adipose tissue was significantly higher in
individuals with GIR <50 μmol kg−1 min−1 (***p<0.001 vs GIR
≥50 μmol kg−1 min−1). (b) Negative correlation of tissue NNMT
expression with insulin sensitivity in insulin-resistant individuals (GIR
<50 μmol kg−1 min−1, n=32, r2=0.41, p<0.001). (c) Positive correlation
between NNMT expression in omental adipose tissue and plasma MNA
concentrations in insulin-resistant individuals (r2=0.44, p<0.001). (d)
Negative correlation of GIR and plasma MNA in insulin-resistant indi-
viduals (r2=0.19, p<0.05). AU, arbitrary units
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p=0.4, Fig. 4b). There was a strong correlation between GIR
and adipose tissue NNMT expression both before (r=0.78,
p<0.001) and after the exercise programme (r=0.70,
p<0.001) (Fig. 4c, d).
Bariatric surgery cohort
In a third group of patients who were morbidly obese (n=55),
NNMTexpression in subcutaneous and omental adipose tissue
and plasmaMNA concentrations were analysed in the context
of a two-step bariatric surgery procedure at the first-step sur-
gery (sleeve gastrectomy) and the second-step surgery (gastric
bypass) 12±2 months after the baseline surgery. Overall an-
thropometric and clinical characteristics of these patients be-
fore first and second surgery are summarised in Table 3.
Sleeve gastrectomy was associated with a significant reduc-
tion in body weight and improvement in glucose homeostasis.
There was a significant reduction in NNMT expression post-
surgery in both subcutaneous (−50%, p<0.001 vs first sur-
gery) and omental (−41%, p<0.001 vs first surgery) adipose
tissue (Fig. 4e). This reduction in expression was reflected by
a significant reduction in plasma MNA concentration (−24%,
p=0.001 vs first surgery, Fig. 4f).
Discussion
This study demonstrates for the first time thatNNMTmRNA in
adipose tissue and circulating levels of the product of NNMT,
MNA, were higher in humans with insulin resistance or type 2
diabetes and correlatedwith the extent of insulin resistance. An
additional novel finding is that interventions improving insulin
sensitivity—exercise and bariatric surgery—are associated
with a decrease in adipose tissue NNMT expression and, for
bariatric surgery, a reduction in plasma MNA levels.
Previously, higher plasma MNA levels had been observed
in patients with type 2 diabetes compared with healthy con-
trols 5 h after a 100 mg nicotinamide challenge [17]. Neither
NNMT expression nor activity was determined in that study
and higher plasma MNA concentrations were attributed to
slower MNA clearance. In addition, there was no significant
difference inMNA plasma concentration between the diabetic
individuals and normal controls before the nicotinamide chal-
lenge. However, the study was comparatively small (N=28),
and no details were given regarding body weight or insulin
resistance in either group of patients. Notably, prolonged treat-
ment (2 weeks) with nicotinic acid or nicotinamide has been
demonstrated to cause insulin resistance in individuals with
NGTor IGT [5–7]. Although noMNA plasma concentrations
were measured in these clinical studies, experiments in rats
demonstrated that nicotinamide administration results in a
marked increase in plasma MNA concentration [17, 18], indi-
cating that a similar rise in plasma MNA can be expected in
humans. Interestingly, administration of either nicotinamide
or MNA to healthy rats had very similar effects on glucose
homeostasis, leading to an increase in both blood glucose and
insulin concentrations. This suggests that the loss of insulin
sensitivity upon nicotinic acid or nicotinamide treatment could
be mediated by MNA.
Higher urinary MNA concentrations were observed in pa-
tients with type 2 diabetes compared with healthy controls and
also in db/db mice and obese Zucker rats [11] and mice on
high-fat diet [19].
Table 2 Anthropometric and clinical characteristics of the exercise-intervention cohort at baseline and after the 12-week exercise programme
Characteristic NGT (n=20) IGT (n=20) Type 2 diabetes (n=20)
Baseline After exercise Baseline After exercise Baseline After exercise
Age, years 33±11 56±12*** 53±7***
Female sex, n (%) 11 (55) 11 (55) 9 (45)
Weight, kg 69.6±14.4 68.2±13.7‡‡ 87.6±16.4*** 84.5±16.2‡‡‡ 94.7±19.7*** 93.0±18.2‡‡‡
BMI, kg/m2 23.3±3.2 22.8±3.1‡‡ 29.6±6.0*** 28.5±5.9‡‡‡ 32.2±6.0*** 31.7±5.5‡
Body fat, % 24.5±3.2 23.3±2.7‡‡‡ 34.9±8.3*** 31.5±7.5‡‡‡ 38.2±8.0*** 35.2±7.7‡‡‡
FPG, mmol/l 5.2±0.5 5.0±0.4 5.7±0.6** 5.5±0.6 6.2±0.6***,†† 5.8±0.5‡‡
2 h glucose, mmol/l 6.0±0.8 5.6±0.6‡‡ 9.4±0.9*** 8.1±1.4‡‡‡ 13.1±1.5***,††† 12.6±2.5
Basal insulin, pmol/l 66±35 58±27‡ 695±493*** 379±324‡‡‡ 319±212***,†† 234±120‡‡
Whole-body glucose uptake, μmol kg−1 min−1 76±17 85±15‡‡‡ 19±9*** 36±16‡‡‡ 21±9*** 32±11‡‡‡
Data are given as mean ± SD for parametric variables or number (column percentage) for categorical variables
**p<0.01 and ***p<0.001 vs NGT (t test)
†† p<0.01 and ††† p<0.001 vs IGT (t test)
‡ p<0.05, ‡‡ p<0.01 and ‡‡‡ p<0.001 vs before exercise (paired t test)
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Importantly, we observed a correlation between plasma
MNA levels and adipose tissue NNMT expression only in
individuals with type 2 diabetes or high BMI but not in those
without diabetes or who had lower BMI (Fig. 2 and ESM
Fig. 1). Although the underlying mechanisms for this obser-
vation are not clear, we postulate that individuals without di-
abetes may be able to mitigate the influence of high WAT
NNMT expression on plasma MNA levels by a mechanism
that is compromised in patients with diabetes. Alternatively,
the contribution of WAT NNMT to circulating MNA concen-
trations relative to other organs, especially liver, may be
higher in insulin-resistant or diabetic individuals. This would
be in line with a report by Riederer et al [9] demonstrating that
high-fat feeding of mice leads to a selective increase in WAT
NNMT activity whereas activity in the liver remains un-
changed.Moreover, mice strains known to be very susceptible
to developing diet-induced obesity were found to have high
WAT NNMT expression whereas WAT NNMT expression was
low in obesity-resistant strains. No such relationship was ob-
served between liver NNMT expression and susceptibility to
diet-induced obesity [10]. Thus, our data may suggest that in
individuals with type 2 diabetes or high BMI, WAT NNMT
makes a larger contribution to circulating MNA levels—lead-
ing to the observed correlation between systemic MNA and
adipose tissue NNMT expression–than in individuals without
diabetes and with a lower BMI. In healthy lean individuals,
liver NNMT activity may predominantly determine circulat-
ing MNA levels. Kraus et al [10] described higher NNMT
protein levels in both WAT and liver in mouse models of type
2 diabetes or diet-induced obesity, though they did not mea-
sure NNMT activity. We cannot exclude the possibility that
increased NNMT activity in the liver of patients with type 2
Fig. 4 Interventions that improve
insulin sensitivity are associated
with reduced adipose tissue
NNMT expression and plasma
MNA concentrations. (a) NNMT
expression in subcutaneous
adipose tissue before (light-grey
bars) and after exercise
intervention (dark-grey bars) for
individuals with NGT, IGT or
type 2 diabetes (n=20 each;
***p<0.001 vs pre-exercise,
paired t test). (b) Intra-individual
change in NNMT expression
(percentage of pre-exercise
expression, **p<0.001 vs NGT,
paired t test) upon exercise. (c)
Correlation between adipose
tissue NNMT expression and GIR
during hyperinsulinaemic–
euglycaemic clamp before the
exercise programme (r2=0.61,
p<0.001) and (d) after the
exercise programme (r2=0.50,
p<0.001). (e) Omental and
subcutaneous WAT NNMT
expression in the context of a
two-step bariatric surgery (n=45;
***p<0.001 vs first surgery,
paired t test). (f) Change in
plasma MNA concentration upon
two-step bariatric surgery (n=38;
**p=0.001 vs first surgery, paired
t test). Light-grey bars, samples
obtained at first surgery; dark-
grey bars, samples obtained at
second surgery 12±2 months
later. AU, arbitrary units; scWAT,
subcutaneous WAT; T2D, type 2
diabetes
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diabetes and obesity may, in addition to increased expression
in WAT, also contribute to the observed associations in these
patients. A limitation of our study is therefore that hepatic
NNMT expression and activity could not be determined, be-
cause liver biopsies were not available for these cohorts.
The correlation between adipose tissue NNMT expression
and insulin resistance—the latter being defined by a low GIR
in the hyperinsulinaemic–euglycaemic clamp—was con-
firmed in two independent cohorts (see Figs 3b, 4c, d). On
the other hand, the association of plasma MNA levels with
GIR was less robust (Fig. 3d) and was only observed in
insulin-resistant individuals. Therefore the value of plasma
MNA as a diagnostic biomarker for insulin resistance is still
limited. The cohorts analysed in our study represent a diverse
clinical spectrum of obesity and insulin resistance over a broad
age range. Although this disease spectrum reflects clinical
reality, it may be associated with confounding factors unrelat-
ed to insulin sensitivity that could influence circulating MNA
levels. Another potential limitation of our study includes the
assessment of total-body fat mass and adipose tissue distribu-
tion using dual-energy x-ray absorptiometry (DEXA), MRI or
computerised tomography scans at only one defined abdomi-
nal segment. We can therefore not rule out the possibility that
using whole-body MRI scans may identify additional correla-
tions of circulating MNA and/or NNMT expression data with
total-body fat mass and fat distribution. Thus, further clinical
studies, preferably with more sophisticated measurements, in
cohorts carefully matched by age, BMI and disease, will be
required to fully explore the usefulness of MNA as a biomark-
er for insulin resistance and to assess its value beyond existing
markers (e.g. high-sensitivity C-reactive protein or HbA1c).
Yet, our data already demonstrate that in individuals with type
2 diabetes or insulin resistance, a high plasma MNA level
indicates a high level of tissue NNMT expression and that
MNA could be used to identify patients eligible for therapy
with an NNMT inhibitor and to monitor their treatment
response.
The mechanisms by which increased NNMT activity and
higher MNA levels could influence insulin sensitivity are un-
clear. Potential pathways may involve the generation of reac-
tive oxygen species [17, 20, 21], an effect on cellular NAD+
levels or sirtuin activity [10, 21–23] or a decrease in cellular
methylation potential (e.g. via lowering the SAM/SAH ratio)
and resulting changes in protein and DNA methylation [10,
18, 24]. For the latter, it is notable thatNNMT is overexpressed
in various forms of human cancer including lung, kidney,
bladder and colorectal cancer [25–28] and oral squamous cell
carcinoma [29]. It has been suggested that MNA could pro-
vide a sink for methyl groups and that the resulting protein
hypomethylation may promote oncogenesis.
In summary, we have demonstrated that adipose tissue
NNMT expression is increased in insulin resistance and type
2 diabetes and correlates with the severity of insulin resis-
tance. Moreover, in insulin-resistant individuals, plasma
MNA is a biomarker for adipose tissue NNMT expression
and the extent of systemic insulin resistance. Thus, NNMT
inhibition may provide a novel therapeutic approach for insu-
lin resistance. The molecular mechanism by which NNMT
could regulate insulin sensitivity is yet unknown and various
possibilities are currently being investigated.
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